(AOF) – Eurobio Scientific published 2023 turnover up 39% to 130.1 million euros for its core business. It increased by 12% like-for-like. The specialist in in vitro medical diagnostics and life sciences had generated a turnover of 152.6 million euros in 2022, including the exceptional turnover linked to the Covid activity, i.e. 59.1 million euros.
International sales are growing strongly and represent 38% of revenues, an increase “mainly linked to new acquisitions made over the past year in Belgium (BMD), the Netherlands (GenDx) and Italy (DID)”.
The Eurobio Scientific group plans to accelerate in 2024 the execution of the strategic axes developed over several years, the development of its own products, internationalization and the opening of new markets.
The group welcomes the “success” of its geographic and technological expansion strategy, with the ambition of becoming “a major international company in the specialty diagnostics market” and offering its customers a “complete offering based on molecular diagnostics with its own solutions and those of its partners”.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.